BLAINVILLE, Quebec, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Duchesnay Inc., member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its...
BLAINVILLE, Quebec, July 24, 2023 (GLOBE NEWSWIRE) -- Duchesnay Pharmaceutical Group is proud to announce it has been named to join the inaugural cohort of the Government of Canada™s Global...
BLAINVILLE, Quebec, June 21, 2022 (GLOBE NEWSWIRE) -- Duchesnay Inc, a pharmaceutical company specializing in women’s health and part of Duchesnay Pharmaceutical Group headquartered in Blainville,...
BLAINVILLE, Quebec, April 27, 2022 (GLOBE NEWSWIRE) -- The Duchesnay Pharmaceutical Group has donated a large quantity of medicines and prescription pre-natal vitamins made at its Blainville,...
BLAINVILLE, QC, Jan. 26, 2021 /CNW/ - Duchesnay, a specialty pharmaceutical company with a long-standing commitment to women's health, is proud to announce a substantial investment at its Blainville, Quebec plant. The addition of a blister packaging line to the production chain for its flagship products Diclectin®, Bonjesta®, Pregvit®, Pregvit® folic 5 and Osphena® will allow the company to increase its export capacity, in addition to optimizing its manufacturing site. This $3 million investment will also help provide and maintain quality specialized jobs in Quebec.
Duchesnay Inc. is pleased to announce that effective immediately, Proctofoam-HC® is back on the Canadian market. A temporary drug shortage, due to a disruption in the manufacturing process has been resolved.
THIS PAST March, Canada’s department of health changed the way it handles the huge amount of data that companies submit when seeking approval for a new drug, biological treatment, or medical device — or a new use for an existing one. For the first time, Health Canada is making large chunks of this information publicly available after it approves or rejects applications.
Duchesnay USA, a pharmaceutical company devoted to safeguarding the health and wellbeing of expectant women and their unborn babies, announced the launch of the Mteryti® family of MultiVitamin / MultiMineral tablets. Each product has a unique AM / PM dosing schedule. The introduction of Mteryti® and Mteryti® folic 5 coincides with International Women's Day, a special time dedicated to celebrate women for their continued contribution to social, economic, cultural and political achievements as well as encourage respect, appreciation and love towards women.
Sometimes it seems that the FDA has a scattershot approach to policing pharma marketing, with warning letters few and far between--and some of them lobbed from left field. But there's one tried-and-true way to invite unwanted attention from the agency's marketing police: Leave side effects out of drug promos, according to an analysis presented at a recent conference.